Logo

Sanofi Presents Results of Olipudase Alfa in Two Clinical Studies at ASHG 2020

Share this

Sanofi Presents Results of Olipudase Alfa in Two Clinical Studies at ASHG 2020

Shots:

  • The P-II/III ASCEND trial involves assessing olipudase alfa 3 mg/kg (IV- q2w) vs PBO in 36 adult patients with ASMD type B to evaluate treatment impact on pulmonary function & spleen & liver volume for 52wks. The study demonstrated improvement in lung function (22% vs 3%)- reduction in spleen volume (39.5% vs 0.5%)- reduction in liver volume (31.7% vs 1.4%); improvement in platelet counts (16.8% vs 2.5%)
  • The P-II ASCEND-Peds trial involves assessing olipudase alfa 3 mg/kg (IV) q2w for 64 wks- in 20 pediatric patients with ASMD without acute or rapidly progressive neurological abnormalities. The study demonstrated 33% increment in predicted DLCO- reduction in spleen volume & liver volume (49% & 41%); 34% increment in platelet count
  • Olipudase alfa is an investigational enzyme replacement therapy designed to replace deficient or defective ASM- allowing for the breakdown of sphingomyelin- currently being investigated to treat non-CNS manifestations of ASMD. The therapy has received FDA’s BT designation- EMA’s PRIME Designation and MHLW’s SAKIGAKE designation

 ­ Ref: Sanofi | Image: Evaluate Pharma

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions